Skip to main content
SpringerLink
Log in

The H-ras oncogene product p21 and prognosis in human breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The protein product of the H-ras oncogene, p21, has been measured semiquantitatively in solubilized particulate fractions of 160 primary tumours from patients presenting without evidence of distant metastatic breast cancer. Levels of p21 have then been related to factors of established prognostic significance, and to clinical outcome after primary treatment in terms of disease-free interval and survival times. p21 was detected by Western blotting in all tumour fractions, but amounts varied markedly between different tumours. There was no significant relationship between levels of p21 and the menopausal status of the patient, tumour oestrogen receptors, grade, and clinical stage. However, there was a significant trend for tumours to be associated with lymph node involvement as p21 was increasingly expressed. Elevated levels of p21 were also significantly related to early disease recurrence and death from cancer. Multivariate stepwise analysis showed that both p21 and lymph node status were independent statistically significant factors for disease recurrence and survival, and that no other parameter was significant for clinical outcome after adjustment for p21 and lymph node status. These results indicate that tumour levels of p21 are an important prognostic variable in patients with early breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bishop JM: Cellular oncogenes and retroviruses. Ann Rev Biochem 52: 301–354, 1983

    PubMed  Google Scholar 

  2. Barbacid M: The role ofras oncogenes in neoplastic development. In: Fortner JG, Rhoads JE (eds) Accomplishments in Cancer Research. General Motors Cancer Research Foundation, 1985, p 179

  3. Ellis RW, DeFeo D, Shih TY, Gonda MA, Young HA, Tsuchida N, Lowy DR, Scolnick EM: The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature 292: 506–511, 1981

    PubMed  Google Scholar 

  4. Langbeheim H, Shih TY, Scolnick EM: Identification of a normal vertebrate cell protein related to the p21 src of Harvey murine sarcoma virus. Virology 106: 292–300, 1980

    PubMed  Google Scholar 

  5. Shih TY, Weeks MO, Young HA, Scolnick EM: Identification of a sarcoma virus coded phosphoprotein in nonproducer cells transformed by Kirsten or Harvey murine sarcoma virus. Virology 96: 64–79, 1979

    PubMed  Google Scholar 

  6. Scolnick EM, Papageorge AG, Shih TY: Guanine nucleotide-binding activity as an assay for src protein of rat-derived murine sarcoma viruses. Proc Natl Acad Sci USA 76: 5355–5359, 1979

    PubMed  Google Scholar 

  7. Furth ME, Davis LJ, Fleurdelys B, Scolnick EM: Monoclonal antibodies to the p21 products of the transforming gene of Harvey Murine Sarcoma Virus and of the cellularras gene family. J Virol 43: 294–304, 1982

    PubMed  Google Scholar 

  8. Gibbs JB, Sigal IS, Poe M, Scolnick EM: Intrinsic GTPase activity distinguishes normal and oncogenicras p21 molecules. Proc Natl Acad Sci USA 81: 5704–5708, 1984

    PubMed  Google Scholar 

  9. Manne V, Bekesi E, Kung HF: Ha-ras proteins exhibit GTPase activity: point mutations that activate Ha-ras gene products result in decreased GTPase activity. Proc Natl Acad Sci USA 82: 376–380, 1985

    PubMed  Google Scholar 

  10. Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G, Barbacid M: Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223: 661–664, 1984

    PubMed  Google Scholar 

  11. Kraus MH, Yuasa Y, Aaronson SA: A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient. Proc Natl Acad Sci 81: 5384–5388, 1984

    PubMed  Google Scholar 

  12. Hand PH, Thor A, Wunderlich D, Muraro R, Caruso A, Schlom J: Monoclonal antibodies of predefined specificity detect activatedras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci USA 81: 5227–5231, 1984

    PubMed  Google Scholar 

  13. Spandidos DA, Agnantis NJ: Human malignant tumors of the breast, as compared to their respective normal tissue, have elevated expression of the Harveyras oncogene. Anticancer Res 4: 269–272, 1984

    PubMed  Google Scholar 

  14. DeBortoli ME, Abou-Issa H, Haley BE, Cho-Chung YS: Amplified expression of p21ras protein in hormone dependent mammary carcinomas of humans and rodents. Biochem Biophys Res Commun 127: 699–706, 1985

    PubMed  Google Scholar 

  15. Ohuchi N, Thor A, Page DL, Hand PH, Halter SA, Schlom J: Expression of the 21,000 molecular weightras protein in a spectrum of benign and malignant human mammary tissues. Cancer Res 46: 2511–2519, 1986

    PubMed  Google Scholar 

  16. Whittaker JL, Walker RA, Varley JM: Differential expression of cellular oncogenes in benign and malignant human breast tissue. Int J Cancer 38: 651–658, 1986

    PubMed  Google Scholar 

  17. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377, 1957

    PubMed  Google Scholar 

  18. Clair T, Miller WR, Cho-Chung YS: Prognostic significance of the expression of aras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 47: 5290–5293, 1987

    PubMed  Google Scholar 

  19. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685, 1970

    PubMed  Google Scholar 

  20. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350–4354, 1979

    PubMed  Google Scholar 

  21. Hawkins RA, Hill A, Freedman D: A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta 64: 203–213, 1975

    PubMed  Google Scholar 

  22. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976

    PubMed  Google Scholar 

  23. Armitage P, Berry G: Statistical Methods In Medical Research. Blackwell Scientific Publications, Oxford, 1987, p.435

    Google Scholar 

  24. Slamon DJ, deKernion JB, Verma IM, Cline MJ: Expression of cellular oncogenes in human malignancies. Science 224: 256–262, 1984

    PubMed  Google Scholar 

  25. Thor A, Hand PH, Wunderlich D, Caruso A, Muraro R, Schlom J: Monoclonal antibodies define differentialras gene expression in malignant and benign colonic diseases. Nature 311: 562–565, 1984

    PubMed  Google Scholar 

  26. Tanaka T, Slamon DJ, Battifora H, Cline JM: Expression of p21ras oncoproteins in human cancers. Cancer Res 46: 1465–1470, 1986

    PubMed  Google Scholar 

  27. Hand PH, Vilasi V, Thor A, Ohuchi N, Schlom J: Quantitation of Harveyras p21 enhanced expression in human breast and colon carcinomas. JNCI 79: 59–65, 1987

    PubMed  Google Scholar 

  28. Lundy J, Grimson R, Mishriki Y, Chao S, Oravez S, Fromowitz F, Viola MV: Elevatedras oncogene expression correlates with lymph node metastases in breast cancer patients. J Clin Oncol 4: 1321–1325, 1986

    PubMed  Google Scholar 

  29. Querzoli P, Marchetti E, Bagni A, Marzola A, Fabris G, Nenci I: Expression of p21ras gene products in breast cancer relates to histological types and to receptor and nodal status. Breast Cancer Res Treat 12: 23–30, 1988

    PubMed  Google Scholar 

  30. Agnantis NJ, Parissi P, Anagnostakis D, Spandidos DA: Comparative study of Harvey-ras oncogene expression with conventional clinicopathologic parameters of breast cancer. Oncology 43: 36–39, 1986

    PubMed  Google Scholar 

  31. Campisi J, Gray HE, Pardee AB, Dean M, Sonenshein GE: Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation. Cell 36: 241–247, 1984

    PubMed  Google Scholar 

  32. Mulcahy LS, Smith MR, Stacey DW: Requirement ofras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature 313: 241–243, 1985

    PubMed  Google Scholar 

  33. Newbold R: Mutantras proteins and cell transformation. Nature 310: 628–629, 1984

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept of Surgery, Royal Infirmary, Edinburgh, UK

    D. M. A. Watson, J. M. Dixon, U. Chetty & W. R. Miller

  2. Medical Statistics Unit, Edinburgh University, UK

    R. A. Elton

  3. The Scottish ancer Trials Office (MRC), The Medical School, The University of Edinburgh, Teviot Place, Edinburgh, UK

    W. J. L. Jack

Authors
  1. D. M. A. Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. A. Elton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. J. L. Jack
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. M. Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Chetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. R. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watson, D.M.A., Elton, R.A., Jack, W.J.L. et al. The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Tr 17, 161–169 (1991). https://doi.org/10.1007/BF01806365

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806365

Key words

Search

Navigation